- LXRP recently received a new U.S. patent allowance for ‘composition of matter’ related to its DehydraTECH™ platform’s delivery of cannabinoids; based on past experience, company expects formal granting of patent within 100 days
- Company filed new U.S. patent application for use of DehydraTECH to improve the speed of absorption of active pharmaceutical ingredients through the skin; compared to other commercial formulations, LXRP product exhibited up to a 225 percent increase in permeability
- LXRP gets primary revenue through third party licensing fees related to its proprietary and patented intellectual property; goal is to partner with leading firms globally to deliver best-in-class products, creating greater shareholder value
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) continues to grow its portfolio of worldwide patents related to the use of its DehydraTECH technology for the delivery of cannabinoids to the body. Not only will these patents enable LXRP to commercialize and defend its IP; they are also expected to generate more revenue stemming from licensing agreements with other companies.
LXRP has continued to add to its existing portfolio of patents in the U.S. and Australia in recent months, with more than 40 patents pending in some 40 countries worldwide. The company’s most recent addition is its new U.S. patent allowance for ‘composition of matter’ for DehydraTECH’s delivery of cannabinoids (http://ibn.fm/t97zK). It also filed a U.S. patent application for technology regarding absorption of active pharmaceutical ingredients through the skin (http://ibn.fm/W3PY2).
LXRP is a British Columbia-based, cannabis-focused food bioscience company, and it is a technology disrupter for edible cannabinoids. Its DehydraTECH technology aids in the body’s absorption of cannabinoids.
The company’s most recent patent filing follows successful laboratory evaluation of DehydraTECH in the transdermal delivery of cannabidiol (CBD). Results showed an increase of up to 225 percent in permeability when compared to control formulations from leading commercial penetration enhancers. The company indicates that it will begin third-party licensing discussions for this new transdermal application as soon as possible, and, based upon past experience, it expects the patent to be formalized within 100 days.
In a news release, John Docherty, president of Lexaria, commented on the U.S. patent allowance approval. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties,” he noted.
For more information, visit the company’s website at www.LexariaBioscience.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.